Tarsus Pharmaceuticals, Inc. (TARS) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
TARS Revenue Growth
Revenue Breakdown (FY 2025)
TARS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
TARS Revenue Analysis (2018–2025)
As of May 8, 2026, Tarsus Pharmaceuticals, Inc. (TARS) generated trailing twelve-month (TTM) revenue of $535.1 million, reflecting explosive growth of +106.9% year-over-year. The most recent quarter (Q1 2026) recorded $162.1 million in revenue, up 6.8% sequentially.
Looking at the longer-term picture, TARS's historical revenue data shows a 3-year CAGR of +159.5%. The company achieved its highest annual revenue of $451.4 million in 2025, representing a new all-time high.
Revenue diversification analysis shows TARS's business is primarily driven by Product (100%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including LNTH (+0.6% YoY), AEYE (+14.5% YoY), and RXST (-19.5% YoY), TARS has outperformed the peer group in terms of revenue growth. Compare TARS vs LNTH →
TARS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TARSCurrent | $535M | +106.9% | - | -15.7% | |
 LNTH | $1.5B | +0.6% | +35.3% | 20.2% | |
 AEYE | $40M | +14.5% | +14.5% | -7.9% | |
 RXST | $134M | -19.5% | +55.7% | -35.8% |
TARS Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $451.4M | +146.7% | $420.7M | 93.2% | $-70,969,000 | -15.7% |
| 2024 | $183.0M | +948.6% | $170.1M | 93.0% | $-120,569,000 | -65.9% |
| 2023 | $17.4M | -32.4% | $15.9M | 90.9% | $-143,158,000 | -820.5% |
| 2022 | $25.8M | -54.7% | $24.9M | 96.3% | $-62,712,000 | -242.9% |
| 2021 | $57.0M | - | $55.0M | 96.4% | $-12,157,000 | -21.3% |
| 2020 | $0 | - | $-246,000 | - | $-26,983,000 | - |
| 2019 | $0 | - | $-74,000 | - | $-4,298,000 | - |
| 2018 | $0 | - | $-1,000 | - | $-1,350,000 | - |
See TARS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TARS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TARS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTARS — Frequently Asked Questions
Quick answers to the most common questions about buying TARS stock.
Is TARS's revenue growth accelerating or slowing?
TARS revenue is accelerating at +106.9% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $535M. Growth momentum has increased versus prior periods.
What is TARS's long-term revenue growth rate?
Tarsus Pharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +106.9% is above this long-term average.
How is TARS's revenue distributed by segment?
TARS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.